Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors

Details Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors

2007-07-31

2007-07-31

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S350000

Reexamination Certificate

active

10875507

ABSTRACT:
The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer

REFERENCES:
patent: 5359073 (1994-10-01), Weier et al.
patent: 5846990 (1998-12-01), Murugesan et al.
patent: 0 260 613 (1988-03-01), None
patent: 0 470 543 (1992-02-01), None
patent: WO 92/06086 (1992-04-01), None
patent: WO 93/14069 (1993-07-01), None
patent: WO 94/12500 (1994-06-01), None
patent: WO 97/29748 (1997-08-01), None
patent: WO 98/06720 (1998-02-01), None
patent: WO 01/00578 (2001-01-01), None
patent: WO 03/024899 (2003-03-01), None
patent: WO 03/032989 (2003-04-01), None
patent: WO 2004/017994 (2004-03-01), None
patent: WO 2004/017995 (2004-03-01), None
Maulik et al, “Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic intervention” Cytokine & Growth Factor Reviews, vol. 13(1), pp. 41-59 (2002).
Ma et al, “c-Met: Structure, Functions and Potential for Therapeutic Inhibition” Cancer Metastasis Reviews, vol. 22(4), pp. 309-325 (2003) as abstracted by Medline.
Elina et al., “Alkyl- and 2-hydroxy derivatives of imidazo[4,5-6]pyrazine and their N-oxides,”Khimiya Geterotsiklicheskikh Soedinenii, 1974, (5), 706-10.
Elina et al., “N-oxides of imidazo[4,5-b]quinoxalines and imidazo[4,5-b]pyrazines,”Khimiya Geterotsiklicheskikh Soedinenii, 1972, (9), 1266-70.
Khanna, et al., “Facile, Regioselective Syntheses of N-Alkylated 2,3-Diaminopyridines and Imidazo[4,5-b]pyridines,”Journal of Organic Chemistry, (1995), 60(4), 960-5, American Chemical Society.
Lovelette et al., “Nonbridgehead fused nitrogen heterocycles. Fused 1,2,3-triazoles,”Journal of Organic Chemistry, 1972, 37(25), 4124-8.
Renz, et al., “Synthesis of 4-aza-5,6-dimethylbenzimidazole and biosynthetic preparation of 4- and 7-aza-5,6-dimethylbenzimidazolylcobamide,”Zeitschrift fuer Naturforschung, C: Biosciences, 1997, 52(5/6), 287-291, Verlag der Zeitschrift fuer Naturforschung.
Wan, et al., “Dienophilicity of imidazole in inverse electron demand Diels-Alder reactions: cycloadditions with 1,2,4,5-tetrazines and the structure of zarzissine,”Tetrahedron, (2001), 57(26), 5497-5507, Elsevier Science Ltd.
Yutilov, et al., “Migration of an N-substituent in imidazo[4,5-b]- and -[4,5-c]pyridines,”Zhurnal Organicheskoi Khimii(1986), 22(2), 445-6.

Affiliated with

Also associated with

Rating

Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3741141